Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 7Skin Neoplasms 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Melanoma, Cutaneous Malignant 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 8cemiplimab 5Nivolumab 4Ipilimumab 4Blood Specimen Collection 3lifileucel 2avelumab 2aldesleukin 2Niacinamide 2Cyclophosphamide 2toripalimab 1tislelizumab 1oxycodone-acetaminophen 1lenvatinib 1fludarabine 1epacadostat 1encorafenib 1durvalumab 1dostarlimab 1brodalumab 1binimetinib 1atezolizumab 1Vitamin A 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1Specimen Handling 1Resistance Training 1Radiotherapy 1Niacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Skin Neoplasms × lifileucel × 90 days × Clear all
NCT07288203 2026-04-20

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Iovance Biotherapeutics, Inc.

Phase 2 Active not recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Iovance Biotherapeutics, Inc.

Phase 3 Recruiting
670 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡